CASI Pharmaceuticals (FRA:ENM) Construction In Progress: €0.00 Mil (As of Dec. 2025)


FRA:ENM CASI Pharmaceuticals Inc FRA:ENM
29 GF Score
Price €1.54
GF Value €11.74
! 5 Warning Signs
View Full Analysis

What is CASI Pharmaceuticals Construction In Progress?

CASI Pharmaceuticals FRA:ENM 29 Construction In Progress is €0.00 Mil as of Dec. 2025. GuruFocus rates FRA:ENM with a GF Score™ of 29/100 and a GF Value™ of €11.74. The stock has 5 warning signs investors should review.

CASI Pharmaceuticals's annual construction in progress declined from Dec. 2023 (€0.02 Mil) to Dec. 2024 (€0.00 Mil) but then stayed the same from Dec. 2024 (€0.00 Mil) to Dec. 2025 (€0.00 Mil).

CASI Pharmaceuticals Construction In Progress Historical Data

* Premium members only.

The historical data trend for CASI Pharmaceuticals's Construction In Progress can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

CASI Pharmaceuticals Construction In Progress Chart

CASI Pharmaceuticals Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Construction In Progress
Get a 7-Day Free Trial Premium Member Only Premium Member Only 10.70 5.41 0.02 0.00 0.00

CASI Pharmaceuticals Quarterly Data
Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25
Construction In Progress Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.00 0.00 0.00 0.00 0.00
FRA:ENM
29GF Score
CASI Pharmaceuticals Inc FRA:ENM
Construction In Progress is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

CASI Pharmaceuticals Construction In Progress Calculation

It records the cost of construction work, which is not yet completed (typically, applied to capital budget items). A construction in progress item is not depreciated until the asset is placed in service. Normally, upon completion, a construction in progress item is reclassified, and the reclassified asset is capitalized and depreciated.

What does a Construction In Progress of €0.00 Mil mean?
CASI Pharmaceuticals (FRA:ENM) has a Construction In Progress of €0.00 Mil as of Dec. 2025. Construction in Progress records the amount of construction work that is not complete. View historical data on CASI Pharmaceuticals and its competitors.
Is CASI Pharmaceuticals' Construction In Progress too high?
CASI Pharmaceuticals' current Construction In Progress is €0.00 Mil. Overall, CASI Pharmaceuticals has a GF Score™ of 29/100, reflecting its overall financial health beyond just this single metric.
How does CASI Pharmaceuticals' Construction In Progress compare to ITRMF and OGEN?
CASI Pharmaceuticals' Construction In Progress of €0.00 Mil can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Construction In Progress for a Biotechnology company?
A good Construction In Progress depends on the Biotechnology industry context. However, Construction In Progress should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Construction In Progress mean?
A high Construction In Progress can signal that a stock is expensive relative to its fundamentals. Construction in Progress records the amount of construction work that is not complete. View historical data on CASI Pharmaceuticals and its competitors. CASI Pharmaceuticals's current Construction In Progress is €0.00 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is CASI Pharmaceuticals stock overvalued right now?
CASI Pharmaceuticals (FRA:ENM) has a current Construction In Progress of €0.00 Mil. The stock's GF Value™ is €11.74, compared to a current price of €1.54 — trading 86.9% below its estimated fair value. The current Construction In Progress is €0.00 Mil. CASI Pharmaceuticals' overall GF Score™ is 29/100 with 5 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Construction In Progress calculated?
Construction In Progress is calculated from a company's financial statements. For CASI Pharmaceuticals (FRA:ENM), the current Construction In Progress is €0.00 Mil as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is CASI Pharmaceuticals (FRA:ENM) Overvalued in 2026?

Based on GuruFocus' analysis, CASI Pharmaceuticals stock appears to be undervalued. The current stock price of €1.54 is trading 86.9% below its estimated GF Value™ of €11.74.

Key valuation signals for FRA:ENM:

  • Construction In Progress: €0.00 Mil
  • GF Value™: €11.74 vs. price of €1.54 (86.9% below fair value)
  • GF Score™: 29/100 with 5 warning signs

No single metric tells the full story. See the FRA:ENM stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

CASI Pharmaceuticals Business Description

Other Exchanges CASIF:USA
Address Jianguo Road, No. 81, Room 1701-1702, China Central Office Tower 1, Huamao Office Building, Chaoyang District, Beijing, CHN, 100025
CASI Pharmaceuticals Inc is a clinical-stage biopharmaceutical company developing CID-103, an anti-CD38 monoclonal antibody, for patients with organ transplant rejection and autoimmune diseases. Additionally, the company manages its other assets, including EVOMELA, FOLOTYN, CNCT19, BI-1206, and CB-5339, with a primary strategic emphasis on advancing CID-103 toward key clinical and regulatory milestones. It also distributes YuTuo (Zimberelimab), a fully human anti-PD-1 monoclonal antibody for patients with relapsed or refractory classical Hodgkin's lymphoma and recurrent or metastatic cervical cancer. Geographically, the company's revenue is solely generated in Mainland China.
29GF Score

Get the complete analysis for FRA:ENM

Construction In Progress is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

€1.54
Price
€11.74
GF Value